Vosoritide
Also known as: BMN 111, BMN-111, modified CNP-39, ProCNP38, Vosoritide, Voxzogo
Source Vosoritide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Vosoritide is a synthetic analogue of the C‑type natriuretic peptide (CNP) that has been approved as a prescription therapy for children with achondroplasia, the most common genetic skeletal dysplasia. By targeting the molecular defect that impairs endochondral ossification, it aims to increase linear growth and improve body proportions in affected pediatric patients.
Mechanism of Action
Vosoritide mimics endogenous CNP and binds to natriuretic peptide receptor B (NPR2) on chondrocytes, raising intracellular cGMP levels. Elevated cGMP antagonises the overactive fibroblast growth factor receptor 3 (FGFR3) signalling that characterises achondroplasia, thereby relieving inhibition of the MAP‑kinase pathway and permitting normal endochondral bone growth.
What the Research Shows
A multicentre, randomised, double‑blind phase 3 trial (2020) showed that daily subcutaneous vosoritide (15 µg/kg) increased annualised growth velocity by 1.57 cm/year versus placebo, with a safety profile limited to mild injection‑site reactions. An open‑label extension (2021) demonstrated persistent growth gains over two years, with velocities rising to ~5.5 cm/year and no new safety signals. A 2026 meta‑analysis of ten real‑world studies (696 children) confirmed similar benefits: a 0.32‑unit rise in height Z‑score after 12 months and an additional 1.82 cm/year of growth, while adverse events remained mild. Reviews (2025) note improvements in body proportions, functional measures, and reductions in lumbar lordosis, but also highlight the need for longer‑term data on adult height and skeletal outcomes.
Reported Benefits
Clinical trials and observational data consistently report that vosoritide adds roughly 1.5–2 cm per year to linear growth in children with achondroplasia, with sustained effects over at least two years. Real‑world analyses echo these gains and suggest modest improvements in body proportion, reduced lumbar lordosis, and enhanced functional capacity such as six‑minute walk distance. The therapy therefore offers a disease‑targeted option that can meaningfully augment height trajectory compared with natural history.
Limitations of the Evidence
Evidence is limited to relatively short‑term follow‑up; the impact on final adult height remains unknown. Study populations are modest in size, and long‑term safety beyond a few years has not been fully established. Data on cost‑effectiveness, health‑related quality of life, and effects on severe skeletal deformities are sparse. Additionally, rare events such as transient hypotension in infants have been reported, underscoring the need for continued monitoring.
Safety Considerations
Vosoritide is generally well tolerated. The most common adverse events are mild injection‑site reactions; transient hypotension has been observed in some infants but is uncommon. No serious treatment‑related adverse events were identified in the pivotal trial or extension studies. Clinicians should monitor blood pressure after initiation, especially in younger children, and counsel families about proper injection technique to minimise local reactions.
How It Is Administered
The drug is supplied as a sterile injectable solution for subcutaneous administration. The approved regimen in trials is a daily subcutaneous injection of 15 µg per kilogram of body weight, typically given by caregivers at home. No oral or other routes are reported.
Routes of Administration
Goals & Uses
- Increase annualized growth velocity in achondroplasiaSkeletal GrowthHigh
- Reduce risk of skeletal complications (e.g., spinal stenosis, foramen magnum narrowing)Disease ModificationLow
- Improve body proportionality and skeletal morphologySkeletal DevelopmentModerate
- Achondroplasia growth promotionIndicationHigh
- Improve quality of life in achondroplasia patientsPatient Reported OutcomesModerate
Contraindications
- Concomitant use of soluble guanylate cyclase (sGC) stimulators (e.g., riociguat)Drug InteractionHigh
- Hypersensitivity to vosoritide or any excipientAllergyHigh
- Hypersensitivity to vosoritide or any excipientsAllergy/hypersensitivityHigh
- Concomitant use of PDE5 inhibitorsDrug InteractionHigh
Adverse Effects
- Hypersensitivity reactionsImmunologicRare
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- Dizziness / syncopeNeurological/cardiovascularUncommon
- Nausea and vomitingGastrointestinalUncommon
- Injection site erythemaLocalCommonRedness at the injection site
- Decreased blood pressure / hypotensionCardiovascularCommon
Drug Interactions
- Soluble guanylate cyclase stimulators (e.g., riociguat)High
- Antihypertensive agentsModerate
- PDE5 inhibitors (e.g., sildenafil, tadalafil)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Adults with closed growth platesEfficacy LimitationRelative
- Patients with cardiovascular disease predisposing to hypotensionCardiovascularRelative
- Children under 5 years of ageAgeAbsolute
- Patients with uncontrolled hypertensionCardiovascularRelative
- Children under 2 years (EU) or under 5 years (US)Pediatric Age RestrictionAbsolute
Regulatory Status
- European UnionApprovedApproved: Achondroplasia in children 5–18 yearsEMA approval 2021.
- United StatesApprovedApproved: Achondroplasia in children 5–18 yearsApproved by FDA in 2021 (brand name Voxzogo).
- United KingdomApprovedApproved: Achondroplasia in children 5–18 yearsApproved by MHRA.
Approved by the FDA in November 2021 for patients with achondroplasia aged 5 years and older. Approved by the EMA in August 2021 for patients aged 2 years and above. Approved by the MHRA in the UK. Breakthrough Therapy designation and Orphan Drug designation granted by FDA.
Evidence & Sources
- Journal ArticleModerateNicolae R, Navardauskaite R, Jee YH2025-01-01T00:00:00.000000Z
- Journal ArticleHighAlbuquerque ALB, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateSavarirayan R, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateJones HL, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateSavarirayan R, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleHighMurton MC, et al.2023-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is vosoritide approved to treat?
Vosoritide is approved as a prescription medication for the treatment of achondroplasia in children, a genetic disorder that limits bone growth and results in short stature.
How does vosoritide promote growth?
It acts as a CNP analogue, binding to NPR2 receptors on growth‑plate chondrocytes, raising cGMP levels, and counteracting the overactive FGFR3 pathway that blocks endochondral ossification, thereby allowing normal bone elongation.
What growth benefit can be expected?
Clinical studies have shown an increase of about 1.5–2 cm per year in linear growth during the first year of treatment, with sustained gains over at least two years and modest improvements in height Z‑score.
What are the common side effects?
Most children experience mild injection‑site reactions such as redness or swelling. Transient low blood pressure has been reported in a small number of infants, but no serious adverse events have been linked to the drug in trials.
Is vosoritide a cure for achondroplasia?
No. Vosoritide does not correct the underlying genetic mutation, but it can increase growth velocity and improve body proportions while treatment is continued. Long‑term effects on final adult height are still being studied.
What is Vosoritide?
Vosoritide is a synthetic analogue of the C‑type natriuretic peptide (CNP) that has been approved as a prescription therapy for children with achondroplasia, the most common genetic skeletal dysplasia. By targeting the molecular defect that impairs endochondral ossification, it aims to increase linear growth and improve body proportions in affected pediatric patients.
What is Vosoritide used for?
Vosoritide is educationally associated with: Increase annualized growth velocity in achondroplasia, Reduce risk of skeletal complications (e.g., spinal stenosis, foramen magnum narrowing), Improve body proportionality and skeletal morphology, Achondroplasia growth promotion, Improve quality of life in achondroplasia patients. Educational only — not medical advice.
How is Vosoritide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Vosoritide?
Reported adverse effects include: Hypersensitivity reactions, Injection site reactions, Headache, Hypotension, Dizziness / syncope, Nausea and vomiting, Injection site erythema, Decreased blood pressure / hypotension. This list is not exhaustive — consult a qualified clinician.
Who should avoid Vosoritide?
Recorded contraindications: Concomitant use of soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), Hypersensitivity to vosoritide or any excipient, Hypersensitivity to vosoritide or any excipients, Concomitant use of PDE5 inhibitors. Consult a qualified clinician before use.